After issues with a batch of Jasper Therapeutics' investigational antibody led to "lower" therapeutic effects in several ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

Shares of Jasper Therapeutics plummeted in premarket trading Monday after the clinical-stage biotechnology company said issues with one lot of its lead drug candidate briquilimab was disrupting ...

Jasper Therapeutics is halving its workforce as part of cost-cutting measures aimed at extending the clinical-stage biotechnology company's runway on the heels of a clinical setback with its lead drug ...

Jasper Therapeutics’ dud drug lot has cost half of the biotech's employees their jobs. | Jasper Therapeutics’ dud drug lot ...

Jasper Therapeutics reports promising SPOTLIGHT study results for briquilimab in treating chronic inducible urticaria with favorable safety outcomes.

“We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,” said Ronald ...

“We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,” said Ronald Martell, ...

REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...